People
Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.
Pfizer has filed a lawsuit against execs at Regor Therapeutics after an investigation pointing company trade secrets were used to develop therapeutics at the center of Regor’s partnership with Eli Lilly.
A new study published in the journal Nature found that two patients with leukemia who were treated with CAR T-cell therapy are still in remission 10 years later.
The global women’s health company took another step in its initiative to encourage healthcare equality for women by declaring March 8, International Women’s Day, an annual holiday.
Pfizer announced that Dr. William Pao, M.D., Ph.D., will take on the role of executive vice president and chief development officer as of March 21.
OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.
Cortexyme, Inc. announced changes to its leadership team, including appointing Christopher Lowe as interim chief executive officer.
This week, two biotechnology firms announced new leadership, David Nassif, J.D., and Christophe Bourdon.
One week after Johnna Rossell departed Biogen for Enzyvant, Biogen announced two more members of its board are leaving.
What makes a candidate attractive? For Deschoolmeester, three critical elements stand out: pragmatism, creativity and collaboration.
PRESS RELEASES